April 2, 2018 07:17 AM EDT

FDA dismisses Alkermes’ pitch on ‘5461, demanding new depression trials in a damaging setback

John Carroll

Editor & Founder

Alkermes $ALKS made a high-stakes gamble that the FDA would consider approving their big depression drug ALKS-5461 on the basis of a single positive Phase …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA dismisses Alkermes’ pitch on ‘5461, demanding new depression trials in a damaging setback

John Carroll

Editor & Founder

Sign up to read this article for free.

Biosecure compromise could add executive review process for named companies, sources say

After UnitedHealthcare CEO killing, healthcare industry faces a new security reality

Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data

Lilly continues to expand its empire of GLP-1 factories with new $3B buildout

GSK's third new pact of the week focuses on Alzheimer's with startup Muna Therapeutics

FDA spells out new expedited withdrawal procedures for accelerated approvals

FDA dis­miss­es Alk­er­mes’ pitch on ‘5461, de­mand­ing new de­pres­sion tri­als in a dam­ag­ing set­back

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Biose­cure com­pro­mise could add ex­ec­u­tive re­view process for named com­pa­nies, sources say

Af­ter Unit­ed­Health­care CEO killing, health­care in­dus­try faces a new se­cu­ri­ty re­al­i­ty

Eli­av Barr de­fends Mer­ck­'s LaNo­va deal, but cau­tions VEGF bis­pecifics have yet to de­liv­er ma­ture da­ta

Lil­ly con­tin­ues to ex­pand its em­pire of GLP-1 fac­to­ries with new $3B build­out

GSK's third new pact of the week fo­cus­es on Alzheimer's with start­up Mu­na Ther­a­peu­tics

FDA spells out new ex­pe­dit­ed with­draw­al pro­ce­dures for ac­cel­er­at­ed ap­provals

FDA dismisses Alkermes’ pitch on ‘5461, demanding new depression trials in a damaging setback

Biosecure compromise could add executive review process for named companies, sources say

After UnitedHealthcare CEO killing, healthcare industry faces a new security reality

Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data

Lilly continues to expand its empire of GLP-1 factories with new $3B buildout

GSK's third new pact of the week focuses on Alzheimer's with startup Muna Therapeutics

FDA spells out new expedited withdrawal procedures for accelerated approvals